Tag Archives: AstraZeneca

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release

What’s new in cancer care across Europe in early 2024 (1 Jan – 5 Mar 2024): Advancements, Innovations, Research, Awareness

(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release

EMA Validates Marketing Authorisation Applications for AstraZeneca and Daiichi Sankyo’s Datopotamab Deruxtecan in Lung and Breast Cancer Treatment

(IN BRIEF) The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for datopotamab deruxtecan (Dato-DXd), developed by AstraZeneca and Daiichi Sankyo, for the treatment of nonsquamous non-small cell lung cancer (NSCLC) and hormone receptor (HR)-positive, HER2-negative breast … Read the full press release

Voydeya Recommended for EU Marketing Authorization as PNH Treatment Add-On

(IN BRIEF) Voydeya (danicopan), a first-in-class oral Factor D inhibitor, has been recommended for marketing authorization in the European Union (EU) as an add-on to ravulizumab or eculizumab for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who experience residual haemolytic … Read the full press release

AstraZeneca and Daiichi Sankyo’s Datopotamab Deruxtecan Moves Closer to Approval for Advanced NSCLC Treatment

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted by the FDA for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) in patients who have undergone prior … Read the full press release

AstraZeneca’s Tagrisso Shows Promise in Phase III LAURA Trial for EGFR-Mutated Lung Cancer

(IN BRIEF) AstraZeneca’s Tagrisso (osimertinib) demonstrates significant improvement in progression-free survival (PFS) for patients with unresectable, Stage III EGFR-mutated non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) in the LAURA Phase III trial. The trial, led by Dr. Suresh Ramalingam, … Read the full press release

FDA Approves AstraZeneca’s Tagrisso Plus Chemotherapy for EGFR-Mutated Lung Cancer

(IN BRIEF) AstraZeneca’s Tagrisso receives FDA approval for treating adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) following a Priority Review. The decision is based on FLAURA2 Phase III trial results demonstrating that Tagrisso plus … Read the full press release

Acoramidis Shows Positive Results in Japanese Trial for Treating Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

(IN BRIEF) In a Phase III trial conducted in Japan, acoramidis, an investigational treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), demonstrated promising high-level results consistent with the global BridgeBio Pharma, Inc. ATTRibute-CM Phase III trial. The trial in Japan aimed to … Read the full press release

Japan Approves Voydeya (danicopan), an Innovative Treatment for Paroxysmal Nocturnal Haemoglobinuria (PNH)

(IN BRIEF) The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for Voydeya (danicopan), a groundbreaking oral Factor D inhibitor, for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is indicated in Japan for use in combination … Read the full press release

AstraZeneca Advances in Cell Therapy with Acquisition of Gracell Biotechnologies

(IN BRIEF) AstraZeneca has announced its definitive agreement to acquire Gracell Biotechnologies Inc. (NASDAQ: GRCL), a global biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. This strategic move aims to bolster AstraZeneca’s presence in the field of … Read the full press release

AstraZeneca Showcases Hematology Advancements and Calquence’s Long-Term Efficacy at ASH Annual Meeting

(IN BRIEF) AstraZeneca is set to unveil promising data at the 65th American Society of Hematology (ASH) Annual Meeting, highlighting its expanding hematology pipeline and the enduring effectiveness of Calquence in treating chronic lymphocytic leukemia (CLL). The presentation includes six-year … Read the full press release

AstraZeneca Launches Evinova: Pioneering Digital Health Solutions for Global Healthcare Advancement

(IN BRIEF) AstraZeneca has introduced Evinova, a groundbreaking venture poised to become a leader in digital health solutions, catering to the needs of healthcare professionals, regulators, and patients. Backed by AstraZeneca and strategically collaborating with Parexel and Fortrea, Evinova is … Read the full press release

AstraZeneca’s Truqap Receives US FDA Approval for Advanced Breast Cancer Treatment

(IN BRIEF) AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has gained approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer possessing specific … Read the full press release

AstraZeneca’s Imfinzi Combination Therapy Shows Promise in Phase III Trial for Liver Cancer Treatment

(IN BRIEF) AstraZeneca has reported positive high-level results from the EMERALD-1 Phase III trial, demonstrating that its drug Imfinzi (durvalumab), in combination with transarterial chemoembolisation (TACE) and bevacizumab, significantly improves progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC) eligible … Read the full press release

AstraZeneca Secures Exclusive License for ECC5004, Promising Oral GLP-1RA for Cardiometabolic Conditions

(IN BRIEF) AstraZeneca and Eccogene have signed an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) designed for the treatment of obesity, type-2 diabetes, and other cardiometabolic conditions. Initial results from the Phase … Read the full press release

AstraZeneca Teams Up with Cellectis to Accelerate Gene Therapy Development

(IN BRIEF) AstraZeneca has entered into a collaboration and investment agreement with biotech firm Cellectis to fast-track the development of cutting-edge therapeutics in areas such as oncology, immunology, and rare diseases. This partnership will leverage Cellectis’ gene editing technologies and … Read the full press release

AstraZeneca’s FluMist Nasal Spray Moves Closer to FDA Approval for Self-Administration

(IN BRIEF) AstraZeneca’s Supplemental Biologics License Application (sBLA) seeking approval for a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray flu vaccine, has been accepted for review by the US Food and Drug Administration (FDA). If approved, … Read the full press release

AstraZeneca and Daiichi Sankyo Gain EU Approval for Enhertu as Monotherapy for HER2-Mutant Lung Cancer

(IN BRIEF) AstraZeneca and Daiichi Sankyo have received European Union (EU) approval for their drug Enhertu as a monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in adult patients with activating HER2 mutations who require systemic therapy … Read the full press release

AstraZeneca: Soliris Gains Approval in China for Rare Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment

(IN BRIEF) Soliris (eculizumab) has received approval in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). This makes Soliris the first and only complement inhibitor approved for NMOSD … Read the full press release

AstraZeneca’s Tagrisso + Chemotherapy Granted Priority Review for EGFR-Mutated Lung Cancer Treatment in the US

(IN BRIEF) AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic epidermal … Read the full press release

AstraZeneca Selects 8 Promising Postdoctoral Researchers to Drive Drug Discovery Innovations

(IN BRIEF) AstraZeneca has revealed the eight winners of its 2023 R&D Postdoctoral Challenge, an initiative that supports early-career scientists in pursuing their innovative research proposals. Unlike traditional industry postdoctoral programs, this unique challenge allows researchers from around the world … Read the full press release

AstraZeneca Highlights Long-Acting Antibodies and Vaccines for At-Risk Individuals at IDWeek Conference

(IN BRIEF) AstraZeneca is set to present new data at the 12th annual IDWeek conference, emphasizing the role of long-acting antibodies and vaccines in safeguarding at-risk individuals from common infectious respiratory diseases. The company will share 15 abstracts, including oral … Read the full press release

Alexion to Present Data Reinforcing Effectiveness of Ultomiris and Soliris in Treating Rare Neurological Disorder at ECTRIMS-ACTRIMS Meeting

(IN BRIEF) Alexion, a subsidiary of AstraZeneca Rare Disease, is set to present new data at the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple … Read the full press release

AstraZeneca Presents Promising Data from Phase III Trials Advancing Cancer Treatments at ESMO Congress

(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance … Read the full press release

Alexion and AstraZeneca Acquire Rare Disease Gene Therapy Portfolio from Pfizer for $1 Billion

(IN BRIEF) Alexion, in collaboration with AstraZeneca Rare Disease, has finalized an agreement to acquire a collection of preclinical rare disease gene therapy programs and related technologies from Pfizer Inc. This strategic move combines the expertise of Alexion and AstraZeneca … Read the full press release

Jacob Lund Appointed as Head of Corporate Communication & Sustainability at Investor

(IN BRIEF) AstraZeneca’s Head of Global Media Relations, Jacob Lund, has been chosen as the new Head of Corporate Communication & Sustainability and a member of the Executive Leadership Team at Investor. With a decade of experience at AstraZeneca, holding … Read the full press release

AstraZeneca Showcases Promising Advances in Lung Cancer Treatments at IASLC Conference 2023

(IN BRIEF) AstraZeneca is advancing its lung cancer portfolio at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer. The company is aiming to have an AstraZeneca medicine for over half of all … Read the full press release

FDA Accepts AstraZeneca’s NDA for Capivasertib Combination Therapy in Advanced Breast Cancer

(IN BRIEF) AstraZeneca’s new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review by the US FDA for the treatment of advanced breast cancer. The NDA is being reviewed under Project Orbis, which … Read the full press release

Innovative Partnership: AstraZeneca and Quell Therapeutics Targeting Autoimmune Diseases with Engineered Treg Cell Therapies

(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release

AstraZeneca to Present Data on Vaccines and Immune Therapies Portfolio at ECCMID 2023

(IN BRIEF) AstraZeneca is set to present data on its Vaccines and Immune Therapies portfolio at the European Congress of Clinical Microbiology & Infectious Diseases. Among the data to be presented will be details on the progress of AstraZeneca’s Vaccines … Read the full press release

AstraZeneca showcases potential of Imfinzi-based treatment for early-stage lung cancer

(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research Annual Meeting. A total of 70 presentations will be given, including a plenary presentation on the AEGEAN Phase III … Read the full press release

Sanofi gains full control of nirsevimab in US with new contractual agreements

(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab) in the United States. Under the new arrangements, Sanofi will have full commercial control of nirsevimab in the U.S. Sanofi … Read the full press release

L’ancien directeur financier du groupe DS Smith rejoint le conseil d’administration de la coopérative

(ACTUALITÉ EN BREF) The Co-operative Group Limited a annoncé qu’Adrian Marsh rejoindrait la société en tant qu’administrateur non exécutif indépendant et président du comité des risques et d’audit. Marsh prend sa retraite de son poste de directeur financier du groupe … Read the full press release

Former DS Smith Group Finance Director joins Co-op Board

(IN BRIEF) The Co-operative Group Limited has announced that Adrian Marsh will join the company as an Independent Non-Executive Director and Chair of the Risk and Audit Committee. Marsh is retiring from his role as Group Finance Director at FTSE … Read the full press release

AstraZeneca cherche la prochaine vague d’innovation thérapeutique avec le défi postdoctoral R&D 2023

(ACTUALITÉ EN BREF) AstraZeneca a lancé le Défi postdoctoral R&D 2023, qui invite les étudiants en dernière année de médecine et/ou de doctorat et les chercheurs postdoctoraux du monde entier à soumettre leurs propres propositions de recherche. L’initiative est conçue … Read the full press release

AstraZeneca seeks next wave of therapeutic innovation with 2023 R&D Postdoctoral Challenge

(IN BRIEF) AstraZeneca has launched the 2023 R&D Postdoctoral Challenge, which invites final-year MD and/or PhD students and postdoctoral researchers from around the world to submit their own research proposals. The initiative is designed to promote diversity of thought and … Read the full press release

AstraZeneca completes acquisition of Neogene Therapeutics, expanding its portfolio in immuno-oncology

(PRESS RELEASE) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of its acquisition of Neogene Therapeutics Inc. Neogene is a global clinical-stage biotechnology company that specializes in the discovery, … Read the full press release

AstraZeneca completa la adquisición de Neogene Therapeutics, ampliando su cartera en inmunooncología

(COMUNICADO DE PRENSA) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueca farmacéutica y de biotecnología, ha anunciado la finalización de su adquisición de Neogene Therapeutics Inc. Neogene es una compañía global de biotecnología en etapa clínica que … Read the full press release

AstraZeneca’s Tezspire receives EU approval for self-administration in a convenient pre-filled pen for severe asthma patients

(PRESS RELEASE) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced that its drug Tezspire (tezepelumab) has been given the green light for self-administration by the European Medicine Agency’s Committee for Medicinal … Read the full press release

Tezspire de AstraZeneca recibe la aprobación de la UE para la autoadministración en una práctica pluma precargada para pacientes con asma grave

(COMUNICADO DE PRENSA) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueco-farmacéutica y biotecnológica, ha anunciado que su fármaco Tezspire (tezepelumab) ha recibido luz verde para la autoadministración por parte del Comité de Medicamentos de Uso Humano (CHMP) … Read the full press release